prikaz prve stranice dokumenta Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer-chemotherapy toxicity and prognostic value
Rad je dostupan svim korisnicima iz sustava znanosti i visokog obrazovanja RH
Znanstveni rad - Izvorni znanstveni rad
Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer-chemotherapy toxicity and prognostic value
Supportive care in cancer, 24 (2016), 11; 4495-4502. https://doi.org/10.1007/s00520-016-3287-y
Srdić, Dražena; Pleština, Sanja; Šverko- Peternac, Ana; Nikolac, Nora; Šimundić, Ana- Maria; Samaržija, Miroslav

Citirajte ovaj rad

Srdić, D., Pleština, S., Šverko Peternac, A., Nikolac, N., Šimundić, A. M. i Samaržija, M. (2016). Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer-chemotherapy toxicity and prognostic value. Supportive care in cancer, 24. (11), 4495-4502. doi: 10.1007/s00520-016-3287-y

Srdić, Dražena, et al. "Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer-chemotherapy toxicity and prognostic value." Supportive care in cancer, vol. 24, br. 11, 2016, str. 4495-4502. https://doi.org/10.1007/s00520-016-3287-y

Srdić, Dražena, Sanja Pleština, Ana Šverko Peternac, Nora Nikolac, Ana Maria Šimundić i Miroslav Samaržija. "Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer-chemotherapy toxicity and prognostic value." Supportive care in cancer 24, br. 11 (2016): 4495-4502. https://doi.org/10.1007/s00520-016-3287-y

Srdić, D., et al. (2016) 'Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer-chemotherapy toxicity and prognostic value', Supportive care in cancer, 24(11), str. 4495-4502. doi: 10.1007/s00520-016-3287-y

Srdić D, Pleština S, Šverko Peternac A, Nikolac N, Šimundić AM, Samaržija M. Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer-chemotherapy toxicity and prognostic value. Supportive care in cancer [Internet]. 2016. [pristupljeno 12.11.2024.];24(11):4495-4502. doi: 10.1007/s00520-016-3287-y

D. Srdić, S. Pleština, A. Šverko Peternac, N. Nikolac, A. M. Šimundić i M. Samaržija, "Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer-chemotherapy toxicity and prognostic value", Supportive care in cancer, vol. 24, br. 11, str. 4495-4502, 2016. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:969354. [Citirano: 12.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:969354
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer-chemotherapy toxicity and prognostic value
AutorDražena Srdić
AutorSanja Pleština
AutorAna Šverko- Peternac
AutorNora Nikolac
MBZ: 266202
AutorAna- Maria Šimundić
MBZ: 235703
AutorMiroslav Samaržija
MBZ: 146943
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za onkologiju i radioterapiju)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Onkologija
Sažetak (engleski)
Cancer cachexia and sarcopenia are frequently observed in non-small lung cancer patients and associated with poor survival. The purpose of our study was to evaluate prevalence of cachexia and sarcopenia in patients with diagnosed advanced NSCLC and their impact on chemotherapy toxicity and time to disease progression, as well as predictive value of several biochemical markers. One hundred patients with advanced IIIB or IV stage of NSCLC that were to start with systemic chemotherapy were recruited in the study. We provided anthropometric and biochemical data and body composition measurements for each patient. Muscle mass was measured by the analysis of electronically stored CT images using lumbar vertebral landmark (L3). Measured muscle area in this region correspond to whole-body tissue quantities. The prevalence of cachexia in our study was 69%, and sarcopenia was present in 47% of patients. We found statistically significant difference between CRP, IL-6 and albumin concentration in cachectic patients and non-cachectic patients. In our study, cachexia and sarcopenia were not predictors of chemotoxicity and survival, but albumin concentration has been shown to be the predictive factor of both chemotoxicity and survival. Biochemical parameters, such as CRP and albumin level have shown to be of more important predictive value in chemotherapy toxicity and survival probability than cachexia and sarcopenia.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaSupportive care in cancer
Brojčani podacivol. 24, br. 11, str. 4495-4502
p-ISSN0941-4355
DOIhttps://doi.org/10.1007/s00520-016-3287-y
URN:NBNurn:nbn:hr:184:969354
Datum objave publikacije2016
URL dokumentahttp://bib.irb.hr/834213
Vrsta resursaTekst
Prava pristupaOgraničen pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2022-02-09 08:16:35